CoQ10 vs Telmisartan
A side-by-side research comparison of CoQ10 and Telmisartan across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | CoQ10 | Telmisartan |
|---|---|---|
| Full name | Coenzyme Q10 (Ubiquinol) | Telmisartan (ARB / Partial PPAR-gamma Agonist) |
| Category | Cardiovascular | Cardiovascular |
| Status | Dietary supplement | FDA-approved drug |
| Mechanism | Shuttles electrons in the mitochondrial respiratory chain (Complex I→III). As ubiquinol, neutralizes lipid peroxyl radicals protecting cell membranes and LDL from oxidation. Restores mitochondrial membrane potential. | Blocks the angiotensin II type 1 (AT1) receptor to lower blood pressure and reduce vascular inflammation, while also acting as a partial PPAR-gamma agonist that improves insulin sensitivity, lipid handling, and mitochondrial biogenesis. |
| Molecular weight | 863.34 Da | 514.62 Da |
| Half-life | ~33 hours (ubiquinol) | ~24 hours |
| Bioavailability | ~6-9% (standard); ~300% improved with ubiquinol/lipid formulations | ~42-58% oral |
| Typical dose | 100-300 mg ubiquinol | 20-80 mg per day |
| Frequency | Daily with fat-containing meal | Once daily |
| Route | Oral softgel | Oral tablet |
CoQ10 reported benefits
- Mitochondrial energy production
- Cardiac function support
- Antioxidant protection
- Statin side effect mitigation
- Exercise performance
- Fertility support (egg/sperm quality)
Telmisartan reported benefits
- Blood pressure control
- PPAR-gamma metabolic benefits
- Improved insulin sensitivity
- Vascular anti-inflammatory effects
- Cardio- and reno-protection
- 24-hour coverage
Related comparisons
Research and educational reference only. Not medical advice.